We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+10.09%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$176M
AUM Growth
+$4.87M
Cap. Flow
-$868K
Cap. Flow %
-0.49%
Top 10 Hldgs %
54.6%
Holding
85
New
17
Increased
11
Reduced
21
Closed
12

Top Buys

Rank Stock Value
1
OCUL icon
Ocular Therapeutix
OCUL
+$3.05M
2
CMPS
Compass Pathways
CMPS
+$2.52M
3
ENGN icon
enGene Therapeutics
ENGN
+$2.23M
4
RLMD icon
Relmada Therapeutics
RLMD
+$1.94M
5
CLDX icon
Celldex Therapeutics
CLDX
+$1.91M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$3.6M
2
KLAC icon
KLA
KLAC
+$2.93M
3
CSTL icon
Castle Biosciences
CSTL
+$2.22M
4
IMNM icon
Immunome
IMNM
+$1.78M
5
PTGX icon
Protagonist Therapeutics
PTGX
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 73.14%
2 Technology 21.04%
3 Energy 4.89%
4 Materials 0.6%
5 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLAC icon
1
KLA
KLAC
$287B
$29.3M 16.67%
198,830
-20,000
-9% -$2.93M
BMY icon
2
Bristol-Myers Squibb
BMY
$124B
$18.6M 10.57%
306,268
+3,426
+1% +$200K
CMPX icon
3
Compass Therapeutics
CMPX
$378M
$7.75M 4.41%
1,465,867
-127,071
-8% -$733K
LRCX icon
4
Lam Research
LRCX
$401B
$7.69M 4.38%
36,000
-4,329
-11% -$968K
STOK icon
5
Stoke Therapeutics
STOK
$1.81B
$6.84M 3.89%
210,000
-50,000
-19% -$1.64M
OVV icon
6
Ovintiv
OVV
$15.9B
$6.38M 3.63%
107,500
– –
NTLA icon
7
Intellia Therapeutics
NTLA
$1.66B
$5.71M 3.25%
445,400
+130,000
+41% +$1.66M
GPCR icon
8
Structure Therapeutics
GPCR
$3.27B
$4.82M 2.74%
100,000
+10,000
+11% +$684K
SLDB icon
9
Solid Biosciences
SLDB
$891M
$4.51M 2.57%
625,980
-79,975
-11% -$514K
PRTA icon
10
Prothena Corp
PRTA
$443M
$4.36M 2.48%
449,019
+8,000
+2% +$73.3K
BDSX icon
11
Biodesix
BDSX
$207M
$4.16M 2.37%
286,804
– –
ACAD icon
12
Acadia Pharmaceuticals
ACAD
$4.39B
$3.81M 2.17%
171,000
– –
PTGX icon
13
Protagonist Therapeutics
PTGX
$8.49B
$3.69M 2.1%
35,000
-20,000
-36% -$1.77M
NBIX icon
14
Neurocrine Biosciences
NBIX
$17.2B
$3.58M 2.04%
27,190
– –
OLMA icon
15
Olema Pharmaceuticals
OLMA
$967M
$3.27M 1.86%
219,000
-50,000
-19% -$1.11M
RLMD icon
16
Relmada Therapeutics
RLMD
$573M
$2.85M 1.62%
+409,387
New +$1.94M
OCUL icon
17
Ocular Therapeutix
OCUL
$2.01B
$2.71M 1.54%
+320,000
New +$3.05M
UTHR icon
18
United Therapeutics
UTHR
$22.5B
$2.67M 1.52%
4,500
+1,500
+50% +$747K
NKTR icon
19
Nektar Therapeutics
NKTR
$2.27B
$2.23M 1.27%
31,000
– –
CLDX icon
20
Celldex Therapeutics
CLDX
$2.78B
$2.22M 1.27%
+70,095
New +$1.91M
NVCR icon
21
NovoCure
NVCR
$1.9B
$2.21M 1.26%
202,330
+50,230
+33% +$627K
EQT icon
22
EQT Corp
EQT
$30.9B
$2.2M 1.25%
34,619
– –
PHAT icon
23
Phathom Pharmaceuticals
PHAT
$875M
$2.17M 1.23%
195,000
– –
BCYC
24
Bicycle Therapeutics
BCYC
$292M
$2.15M 1.22%
463,599
+899
+0.2% +$5.14K
CMPS
25
Compass Pathways
CMPS
$1.68B
$2.07M 1.18%
+375,000
New +$2.52M
1
2 3 4

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Birchview Capital held 85 positions worth $176M, up 2.8% from $171M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Birchview Capital's Q1 2026 filing shows 17 new, 11 increased, 21 reduced and 12 closed positions. Its largest new stake was Ocular Therapeutix: 320,000 shares worth $2.71M. The largest sale was Amicus Therapeutics, an estimated $3.6M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 76% a quarter earlier, followed by Technology and Energy.

  • Birchview Capital's largest Q1 2026 buy was Ocular Therapeutix: 320,000 shares worth $2.71M.
  • Birchview Capital added most to Pacific Biosciences in Q1 2026, an estimated $1.79M increase.
  • Birchview Capital's biggest Q1 2026 reduction was KLA, cutting an estimated $2.93M.
  • Birchview Capital fully exited Amicus Therapeutics in Q1 2026, selling an estimated $3.6M.
  • Birchview Capital's ten largest holdings make up 55% of its $176M portfolio in Q1 2026.
  • Birchview Capital opened 17 new positions and closed 12 in Q1 2026.
  • Birchview Capital's portfolio value rose 2.8% quarter-over-quarter to $176M.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.